Organ transplantation can be carried out to prolong their lives when patients get end-stage organ failure. However, organ structure and function damage and immune rejection after transplantation impair patients' survival time and quality. Cell therapy has been widely accepted as an effective way in regenerative medicine and it is mainly divided into stem cell therapy and immune cell therapy. Cell therapy has achieved significant therapeutic effect in organ transplantation. Taking kidney transplantation as an example, this paper will discuss how to regulate the immune balance of organ transplantation and prolong the vitality of transplanted organs and patients by cell therapy. These will provide new insights for the induction and maintenance of organ transplantation tolerance.

Objective To investigate the therapeutic effect of the CD166⁺subpopulation of bone-associated mesenchymal stem cells applied in inflammatory bowel disease (IBD). Methods After removing bone marrow cells from the femur and tibia of C57/BL6 mice, we performed collagenase digestion to obtain bone-associated cells, and sorted CD166⁺MSCs using an MSC enrichment kit and a CD166-positive magnetic bead sorting kit. A mouse model of IBD was induced using 3% dextran sodium sulfate (DSS), and the successfully molded mice were equally divided into the CD166⁺MSCs-treated and control groups. Mice in the CD166⁺MSCs-treated group were given an intravenous infusion of CD166⁺MSCs, while the control group was given PBS. The mice were observed daily for bloody stool, and body weight was recorded. After three days of infusion, the colon length of mice in each group was examined, and pathological tissue slices were stained and analyzed to observe the histopathological changes in the colon. Results Compared with the control group, the CD166⁺MSCs-treated group showed significantly less blood in the stool, significantly longer colon length, less destruction of the crypt in pathological tissue slice, more goblet cells, and lower histopathological score. Conclusion Transplantation of CD166⁺MSCs in the IBD disease model resulted in a better therapeutic effect.

Objective We aimed to establish a relatively complete operation procedure for platelet storage using classical SSP+ platelet additive solution, and to compare the quality of preserved platelet concentrates in SSP+ versus in plasma. Methods Eighty-four blood （400 mL/person） were randomly collected from the general population in Chongqing. A buffy coats product derived from the whole blood donations of 6 same blood type donors were pooled to make a buffy coats platelet concentrate（n=14）. Each pool was divided into two groups, suspended in SSP+ and plasma, respectively. Platelet count, pH, MPV, platelet metabolism, hypotonic shock response（HSR）, CD62p expression and apoptosis indicator （AnnexinⅤ） were measured on Days 1, 5 and 7. Results There were no significant differences in platelet concentration, content, volume, MPV and pO₂ during 7 days of storage between SSP+ group and plasma group （P>0.05）. However, the pH value in SSP+ group was significantly higher than that in plasma group （P<0.05）. The glucose consumption in SSP+ PAS group and the corresponding increase of lactic acid was significantly lower than that in plasma group （P<0.05）. With the decrease of pCO₂, CO₂ emission increased. The consumption of bicarbonate in additive SSP+ group was significantly lower than that in plasma group （P<0.05）. The HSR in SSP+ group was higher than that in plasma group. Both the CD62p expression and AnnexinⅤ were lower than that in plasma group. All products were performed the test for sterility on the 7th day of storage, and the results were negative. On the 7th day of storage, the pH and MPV in SSP+ group were still remained 6.94 ±0.11 and 9.89±0.52, respectively. Conclusion Platelets concentrates suspended in the classical SSP+ could metabolize normally within 7 days of storage. It has better in vitro parameters in platelet metabolism, platelet activation and apoptosis.

Objective To investigate the inhibitory efficacy of platelet-rich plasma (PRP) in frozen and lyophilized forms against four common infectious bacteria and to compare the differences in inhibition. Methods Fresh platelets from healthy volunteers were collected by blood apheresis machine and prepared into frozen PRP and lyophilized PRP, which as experimental groups. We set saline as control group and observed whether above 3 groups could inhibit the growth of Staphylococcus aureus (S. aureus), Escherichia coli (E. coli) and Candida albicans (C. albicans) and Pseudomonas aeruginosa (P. aeruginosa) at different time points by coated plate counting method. Results Compared to saline group, both frozen PRP and lyophilized PRP groups inhibited the growth of S. aureus, E. coli and C. albicans, and increased P. aeruginosa growth. At each point, frozen PRP and lyophilized PRP groups showed significant inhibitory effects against S. aureus, E. coli and C. albicans. There were significant differences in bacteriostasis at some points between the frozen PRP and lyophilized PRP groups. Conclusion Both frozen PRP and lyophilized PRP have antibacterial effects with specific antibacterial spectrum and timeliness, and lyophilized PRP has stronger effects than frozen PRP.

Objective To explore the safe blood transfusion strategy for thalassemia in children in Yunnan Province. Methods A total of 2 620 children diagnosed with thalassemia who received once or repeated blood transfusions in eight cities with a high incidence of thalassemia in Yunnan Province before（from 2012 to 2016）and after （from 2017 to 2021） the implementation of the safe blood transfusion strategy were selected. The positive rate of screening antibodies and the incidence of adverse reactions in blood transfusion were compared. Results After the implementation of the strategy,the positive rate of screening antibodies and the incidence of adverse reactions in blood transfusion were significantly reduced. The positive rate of screening antibodies decreased from 33.62% to 7.64%,and the incidence of adverse reactions in blood transfusion decreased from 4.31% to 0.36%,and the differences were statistically significant（P<0.01）. Conclusion The safe transfusion strategy is scientific,reasonable and effective. The detection of ABO,Rh-CcDEe and MNSs blood group antigen and screening antibodies should be performed in practice in children with thalassemia. Prophylactic ABO,Rh-CcDEe and MNSs antigen-matched blood is transfused to ensure the safety and effectiveness of transfusion therapy.

Objective To analyze the influence of anti-M antibody on blood transfusion compatibility test,the necessity of such antibodies for transfusion compatibility detection and clinical transfusion was found in advance, and then the importance of O cells in daily blood group identification was further explored. Methods The ABO typing discrepancy specimens were collected in the first blood group typing in the Department of Blood Transfusion of our hospital from January 2019 to December 2021, 18 of them were found to be anti-M positive by anti-human globulin test and other methods, and the influence of anti-M was eliminated by absorption-elution test and 2-mercaptoethanol. The red blood cells and serum after treatment were confirmed by forward and reverse typing, and cross-matching experiments were carried out by saline method, polybrene method and antiglobulin test. Results Among the 18 anti-M positive samples, 16 blood typing with discrepancy, antibodies were detected in reverse typing, 2 cases of type O specimens were not detected by automatic blood typing instrument, and O cells were found to be positive when the reverse type was rechecked by test tube method. After the anti typing of serum was rechecked by O cell absorption, the forward and reverse typing of all samples were consistent, and anti-M antibodies were detected in antibody identification. Cross matching test was carried out in 14 cases, of which 4 cases were infused with suspended red blood cells and other blood components, there was no adverse reaction of blood transfusion. The efficacy evaluation after blood transfusion found that the infusion was effective. Conclusion For the samples clearly caused by anti-M inconsistent match or cross blood incompatible, the interference caused by anti-M antibody can be eliminated and the correct experimental results can be obtained after the serum is treated with absorption test and 2-mercaptoethanol. However, the automatic blood group instrument alone is used to detect the blood group-deficient O cells with the cold-reactive saline antibodies to the anti-M class.

Objective To discuss the associations between preoperative anemia, perioperative transfusion, and postoperative outcomes in children with congenital heart disease(CHD). Methods Data recorded for 89 children underwent their first selective operation in our hospital were retrospectively collected from the blood transfusion information management system (BLOOD) and SPSS software. Data included clinical data, relevant lab test results, perioperative transfusion and prognosis and outcomes. Patients were divided into two groups: anemia group (n=22) with a history of preoperative anemia and non-anemia group (n=67) without. Univariate analysis and linear regression model examined the effect of preoperative anemia on the perioperative transfusion and postoperative outcomes in children with congenital heart disease. Results The incidence of preoperative anemia was 24% (22/89). There was no significant difference in intraoperative blood loss, urine volume, ultrafiltration volume, cardiopulmonary bypass time, and aortic occlusion time between the two groups (P>0.05). However, the perioperative RBC transfusion and cryoprecipitate infusion were higher, and mechanical ventilation time, ICU stay and hospital stay were all prolonged in anemia group, with statistically significant difference (P=0.003, 0.017, 0.005, 0.003, 0.005,respectively). Conclusion Preoperative anemia can increase perioperative RBC transfusion and cryoprecipitate transfusion, and prolong mechanical ventilation time, postoperative ICU stay and hospital stay. Those were risk factors of poor prognosis.

Objective To explore the effect of platelet rich plasma (PRP) on traumatic synovitis of ankle joint. Methods From January 2021 to June 2022, 45 patients with traumatic synovitis of the ankle joint who were treated in the department of orthopedics and traumatology of a tertiary hospital were included. The patients were randomly divided into the observation group (20 cases, PRP treatment) and the control group (25 cases, traditional corticosteroid treatment) according to the random number table method. The ankle joint scores and clinical effects were compared between the two groups at before, 1, 3 and 6 months after treatment. Results The Baird-Jackson score and AOFAS score were higher (P<0.05) and VAS score was lower than before treatment in both groups after 1 month of treatment (P<0.05), and the control group was better than observation group (P<0.05). After 3 months of treatment, Baird-Jackson score and AOFAS score decreased (P<0.05) and VAS score increased (P<0.05) in the control group compared with one month after treatment. Baird-Jackson score and AOFAS score increased (P<0.05) and VAS score decreased (P<0.05) in the observation group compared with one month after treatment ( P<0.05), which was better than the control group (P<0.05). Time to first improvement in the control group was more common in 24 hours after treatment, and which was more common in 2 weeks and 1 month after treatment in the observation group (P<0.05). The total effective rate of the observation group was 95%, higher than that in the control group of 68% (P<0.05). Conclusion Traditional hormone therapy is fast-acting but short-sustained and prone to recurrence. PRP has better long-term effects and can improve patients' clinical symptoms for up to 6 months, which is worthy of clinical application.

Objective To investigate the characteristics of blood use and influencing factors of allogeneic blood transfusion in elderly orthopedic patients, thus providing information beneficial to the clinical management of blood use for such patients. Methods A total of 648 orthopedic patients age≥60 years were included, with 598 undergoing surgery and 50 conservative treatment. The blood use characteristics of surgical and conservative treatment groups were compared and analyzed. According to the disease classification and characteristics of blood use in surgery, 598 elderly patients undergoing orthopedic surgery were divided into eight groups. According to whether the patients received allogeneic transfusion or not, 598 patients were assigned into the transfusion group and the non-transfusion group. Preoperative baseline data, perioperative hemorheology indexes, autologous blood dosage, length of stay and in-hospital mortality were compared between the two groups, and their P values were calculated. Two groups were selected to compare P<0.1 variables, surgical classification and autotransfusion volume, etc, establish multiple multivariate logistic regression equation, and finally analyze the main factors affecting allogeneic blood transfusion in elderly orthopedic surgery patients. Results The variables influencing perioperative allogeneic blood transfusion in elderly orthopaedic surgery were Hb (OR: 0.948, P<0.001), cerebral infarction medical history (OR: 1.844, P=0.034), intraoperative blood loss (OR:1.005, P<0.001), intraoperative autotransfusion volume (OR: 0.995, P=0.005), orthopedic surgery classification (OR: 1.466, P<0.001) and postoperative D-dimer (OR:1.111, P=0.038). Conclusion Preoperative Hb and intraoperative autotransfusion volume were protective factors for allogeneic transfusion in elderly patients undergoing orthopedic surgery. History of cerebral infarction, intraoperative blood loss, orthopedic surgery classification (from low to high probability of transfusion) and postoperative D-dimer were the risk factors for allogeneic transfusion in elderly patients undergoing orthopedic surgery.

Objective To establish a multivariate prediction model for platelet transfusion in patient with severe postpartum hemorrhage (PPH) to provide a basis for the clinical formulation of platelet transfusion. Methods A total of 319 maternities with severe PPH successfully treated in Women's Hospital of Nanjing Medical University between January 2008 and May 2021 were retrospectively analyzed. The patients were divided into two groups: platelet transfusion group (64) and no platelet transfusion group (255) based on platelet transfusion. Predictors included age, body mass index (BMI), mode of delivery, pregnancy comorbidities and complications including amniotic fluid embolism, abruptio placentae, stillbirth, preeclampsia, HELLP syndrome, moderate to severe liver function abnormalities (≥3-fold increase in transaminases), amount of postpartum hemorrhage, presence of occult hemorrhage (including intra-abdominal hemorrhage, subperitoneal hematoma, and vaginal wall hematoma) that could not be counted accurately, amount of transfused red blood cell suspensions, platelet count before delivery, and whether hemorrhagic shock or disseminated intravascular coagulation occurred during resuscitation. Risk factors for platelet transfusion were identified and R software was used to create a nomogram prediction model. The performance of nomogram was evaluated by using a bootstrapped-concordance index and calibration plots. Receiver operating characteristic (ROC) analysis was used to compare the diagnostic efficacy of the nomogram model and other independent predictors. Results Binary logistic regression analysis showed that amount of postpartum hemorrhage, amount of red blood cells transfused, platelet count before delivery, presence of occult hemorrhage, placental abruption, preeclampsia and moderate to severe liver function abnormalities were independent risk factors for predicting severe reduction in platelets. The nomogram model constructed based on the amount of postpartum hemorrhage, amount of transfused red blood cell suspensions, platelet count before delivery, presence of occult hemorrhage, placental abruption, preeclampsia and moderate to severe liver function abnormalities has the highest AUC value of 0.789. The AUCs for the independent influencing factors of platelet transfusion in patients with severe postpartum hemorrhage applied alone for the amount of postpartum hemorrhage, the amount of transfused red blood cell suspensions, platelet count before delivery, presence of occult hemorrhage, placental abruption, platelet count, preeclampsia and moderate to severe liver function abnormalities before delivery were 0.631, 0.689, 0.518, 0.611, 0.641, 0.531 and 0.529, respectively. Conclusion The multivariate prediction model of platelet transfusion in patients with severe PPH based on Nomogram has high predictive efficacy. It can guide clinical foresight to prepare platelets in advance and provide a basis for timely control of platelet transfusion timing and formulation of platelet transfusion plan in severe PPH.

Objective To investigate the effectiveness of reagents and assays suitable for screening tests for accidental antibodies to the red blood cell blood group system in daratumumab-treated patients. Methods Red blood group antibody screening cells were treated with 0.2 mol/L dithiothreitol（DTT） and 0.01 mol/L DTT,and the plasma of 13 patients treated with darettuzumab was accidentally screened for antibodies using the treated reagent red blood cells（microcolumn gel method）. The hemolysis degree,antigenicity of blood group antigen and red blood cell count were measured after treatment. Results Both concentrations of reagent red blood cells were uniformly detected. Negative results from the unexpected antibody screening test were observed in 11 patients,and unexpected antibodies（anti-E）in 2. Hemolysis occurred in 0.2 mol/L DTT treated reagent red blood cells on the 5th day of storage at 4℃,while there was no hemolysis within 31 days after treatment with 0.01 mol/L DTT,and red blood cell count was not statistically different from that of untreated reagent cells（P=0.59,0.40,0.78,all greater than 0.05）. The agglutination intensity of erythrocytes D,Fy^a,Fy^b,M,N,C,c,E,e,JK^a,JK^b,Le^a,Le^b,P1 and S antigens remained unchanged, but the agglutination intensity of K and k antigens was reduced. Conclusion After 0.01 mol/L DTT treatment,RBC blood group antibody screening cells could be used to detect unexpected antibodies in the RBC blood group system of patients receiving darettuzumab treatment,effectively eliminate the interference of darettuzumab and identify alloantibodies. Moreover,long-term storage can be achieved at 4℃,which does not necessitate temporary treatment of reagent red blood cells, thus saving the test time.

Objective Anti-G antibodies in prenatal serological testing were identified to distinguish anti-G from anti-D and both anti-D and anti-C antibodies. O-type ccDEE and Ccdee cells were used as adsorbed cells, and“double adsorptions”was used. Methods The ccDEE and Ccdee cells less reported were selected as adsorbed cells, double adsorptions were performed. ABO blood typing, Rh typing, direct Combs test, irregular antibody screening and antibody titer detection and other tests were used to identify Anti-G. Results The experimental design and method can effectively identify anti-G and distinguish anti-D and anti-C from anti-G. Conclusion O-type ccDEE and Ccdee cells were used as adsorbed cells. The double adsorptions were used to identify Anti-G. The cell source was wide, the absorption time was saved, and the identification result was accurate.

Objective To investigate the hemolysis rate of red cell suspensions during the late storage period from donors with different genders and ages, and thus provide data beneficial to scientific research on blood service and blood quality control. Methods From June 2012 to June 2021, 400 bags of 1 unit suspended red blood cells were randomly sampled, and the hemolysis rate was measured by aseptic sampling on day 35 during the late storage period. The data of hemolysis rate were grouped according to the sex and age of blood donors. Results The mean hemolysis rate during the late storage period was 0.20%, among which the hemolysis rate of the male group was higher than that of the female group, and the hemolysis rate of the 18-30 year old group was lower than that of the 31~40 year old group and that of the ≥41 years old group, respectively, with significant differences between the groups. Logistic regression equation showed that compared with the female group, the male group had an increased risk of hemolysis; and the 30~40 years old group and ≥41 years old group reported a higher risk of hemolysis than the 18~30 years old group, the difference being statistically significant. Conclusion Our findings suggest that the sex and age of blood donors are among the important factors affecting hemolysis rate, which could provide an accurate and detailed reference range for clinical quality control.

Objective To analyze the expression of antinuclear antibodies (LIA-ANAs) in patients with chronic hepatitis C and the relationship of LIA-ANAs with HCV-RNA and HCV genotype. Methods A total of 149 patients with chronic hepatitis C and 93 healthy participants from the First Affiliated Hospital of University of Science and Technology of China were recruited in this study from April 2019 to April 2022. The expression levels of LIA-ANAs were detected by western blotting. HCV-RNA and HCV genotype were detected by PCR-fluorescent probe and PCR-reverse dot hybridization, respectively. Results Among the 149 patients, 56 were HCV-RNA positive and 93 were negative. LIA-ANAs were detected in 25 of 56 HCV-RNA positive chronic hepatitis C patients, with a positive rate of 44.6%; 21 LIA-ANAs were detected in 93 HCV-RNA negative patients, with a positive rate of 22.6%; and the difference between the two groups was statistically significant (P=0.004 8). The 56 HCV-RNA positive patients were divided into high and low groups in terms of copy amount. There was no significant difference in the positive rate of LIA-ANAs between the two groups (P=0.578 9). Furthermore, the positive rate of cytoplasmic antibody in the HCV-RNA positive group was higher than that in the HCV-RNA negative group, with the difference being statistically significant (P=0.020 4). The HCV-RNA positive group was similar in the rate of positive ANA titer to the HCV-RNA negative group (P=0.124 9). The main HCV genotype in the patients was type 1b, accounting for 80.4% (45/56); however, no significant difference was observed in the LIA-ANAs detected in the serum of patients with different HCV genotypes (P=0.244). Conclusion Compared with the healthy group, the expression of serum LIA-ANAs in patients with chronic hepatitis C was significantly increased, and the expression of LIA-ANAs in active chronic hepatitis C patients was significantly higher than that in inactive patients. This finding suggests that patients with chronic hepatitis C need regular monitoring of LIA-ANAs to intervene in the occurrence of related complications.

Objective To explore the clinical characteristics, efficacy evaluation, risk factors for disease progression and survival prognosis of patients with primary mediastinal large B-cell lymphoma (PMBCL). Method The clinical data of 16 patients with PMBCL from March 2015 to February 2022 in First Affiliated Hospital of USTC (Anhui Provincial Hospital) were retrospectively analyzed. The clinical characteristics and prognosis of the patients were statistically analyzed. Results The median overall survival (OS) time of 16 patients with PMBCL was not reached, and the 5-years OS rate was 92.3%. And the median progression-free survival (PFS) time was 7 (95%CI: 6.5~15.5) months, and the 5-years PFS was 43.3%. As of the follow-up date, the median follow-up time was 25 (4~70) months. One (1/16, 6.3%) patients was lost to follow-up, 14 (93.3%) patients was alive, in which 8 patients reached complete remission (CR) and 5 patients reached partial remission (PR), and the overall response rate (ORR) was 86.67%. The ORR was 75% in patients with refractory relapse PMBCL after using PD-1 inhibitor. Univariate analysis showed that Ann Arbor stage, group B symptoms, LDH level, whether there was a huge mass, aa-IPI score, whether SUV Max and mum-1 were positive in PET-CT lesions, and different Ki-67 levels were not risk factors for PMBCL disease progression. Conclusion The OS in the patients with PMBCL, who received induction chemotherapy treatment containing rituximab, has been improved. However, the PFS has not been improved well and the new regimen is needed to achieve the goal of cure in patients. The regimen containing PD-1 inhibitor can be considered for patients with relapsed and refractor PMBCL.

Objective To investigate the levels of serum interleukin-6 (IL-6) and fibroblast growth factor-23 (FGF-23) in hemodialysis patients with chronic renal failure (CRF), and to analyze the relationship between them and protein-energy wasting (PEW). Methods 150 patients with CRF treated in the hospital from August 2018 to August 2021 were selected as the research subjects. All patients received maintenance hemodialysis and were followed up for 24 weeks. According to the occurrence of PEW at the end of follow-up, the patients were divided into occurrence group and non occurrence group; the baseline data questionnaire of patients was designed at admission, and the initial baseline data and laboratory indexes of patients in the two groups were compared; the relationship between the initial serum levels of IL-6 and FGF-23 and pew in hemodialysis patients with CRF was mainly analyzed. Results The incidence of PEW in 150 hemodialysis patients with CRF was 24.67% (37/150); compared with the non occurrence group, the proportion of insufficient dialysis in the occurrence group was higher, and the levels of initial blood creatinine (SCR), C-reactive protein (CRP), IL-6 and FGF-23 were significantly higher, the differences were statistically significant (P<0.05); the results of Logistic regression analysis showed that, insufficient dialysis, high levels of initial SCR, CRP, IL-6 and FGF-23 were the risk factors of PEW in hemodialysis patients with CRF (OR>1, P<0.05); the results from the decision curve showed that, in the range of high risk threshold 0.0~1.0, the combination of serum IL-6 and FGF-23 can predict the net benefit rate of PEW in hemodialysis patients with CRF, which was of clinical significance; by restricted cubic spline analysis, the results showed that, there was a linear dose-response relationship between IL-6 and FGF-23 and PEW in hemodialysis patients with CRF (P<0.05). Conclusion The levels of serum IL-6 and FGF-23 are related to the occurrence of PEW in hemodialysis patients with CRF.

Objective To evaluate the significance of activity ratio of pyruvate kinase （PK） to glucose-6-phosphate dehydrogenase（G6PD）in the diagnosis of PK deficiency. Methods A total of 40 patients diagnosed with pyruvate kinase deficiency（PKD）in the department of blood transfusion at our hospital from January 2015 to January 2022 were retrospectively analyzed. Healthy peoples made up the control group. The differences between the two groups in blood count, reticulocyte percentage（Ret）, peripheral blood smear and PK/G6PD activity ratio（recommended by ICSH） were compared, and the relationship between each index and PKD was analyzed. Results Compared with the control group, RBC decreased, Ret increased and PK/G6PD ratio decreased significantly in the PKD group（P<0.05）. The Pearson correlation coefficient between PK/G6PD ratio and PK activity was 0.913, and the area under the ROC curve when evaluating the diagnosis of PKD was 0.972（95% CI: 0.941~1.002）. The decrease of PK/G6PD ratio in heterozygotes was more severe than that in non-heterozygotes. Conclusion The ratio of PK/G6PD and the activity of PK have the same diagnostic value, especially for patients with increased reticulocyte and transfusion dependence. For PKD with recessive genetic defects, pedigree analysis is strong evidence for diagnosis.

Objective To investigate the clinical efficacy of different doses of anthracycline idarubicin in the induction treatment of acute myeloid leukemia（AML）for adults aged less than 60. Methods A total of 265 young AML patients（14~59 years old）were diagnosed at our center from June 2015 to December 2019. We retrospectively reviewed 239 patients treated with the regimen of idarubicin combined with cytarabine（IA 3+7）,focusing on complete remission（CR）rate,recurrence and long-term survival in patients with different prognostic risk groups. Results After the first induction therapy,61（65.6%）and 103（70.6%） patients in the IDA 8 mg/m² group and the IDA 10~12 mg/m² group obtained morphological CR（P=0.475）,of which 26 patients（42.6%）in the IDA 8 mg/m² group and 64 patients（62.1%）in the IDA 10~12 mg/m² group had minimal residual disease（MRD）negativity. The 3-year cumulative incidence of relapse（CIR） was 45.1%（95% CI：34.1%~57.8%）in the IDA 8 mg/m² group and 49.6% （95% CI：40.7%~59.3%） in the IDA 10~12 mg/m² group（P=0.469）. The 3-year overall survival（OS）rate was lower in the IDA 8 mg/m² group [34.6%（95% CI：24.9%~44.4%）] than in the IDA 10~12 mg/m² group [46.6%（95% CI：38.2%~54.6%）] （P=0.038）. For intermediate-risk patients,the 3-year OS rate for patients in the IDA 8 mg/m² group was 31.5%（95% CI：18.9%~45.0%）,which was significantly lower than that in the IDA 10~12 mg/m² group [43.7%（95% CI：32.3%~54.6%）] （P=0.043）. The 3-year event-free survival（EFS） rate in the IDA 8 mg/m² group and the IDA 10~12 mg/m² group were 32.0% （95% CI：22.7%~41.6%）and 37.0%（95% CI：29.2%~44.8%）respectively（P=0.319）. For intermediate-risk patients, there was a lower trend of the 3-year EFS rate in the IDA 8 mg/m² group [25.4%（95% CI：14.0%~38.4%）] than in the IDA 10~12 mg/m² group [33.3%（95% CI：23.0%~44.0%）] （P=0.107）. There were no significant differences in the 3-year OS rate and 3-year EFS rate between the favourable risk group and the adverse risk group. Conclusion For young adult patients with AML,the induction therapy with IA (3+7) regimen based on idarubicin 10~12 mg•m^-2•d^-1×3 d could achieve higher immunological remission and better long-term survival,especially for patients with intermediate risk according to 2017 ELN risk stratification.

Objective To evaluate and analyze the clinical EMR (early molecular response) efficacy of nilotinib in first-line treatment of chronic myeloid leukemia (CML), and to explore the related factors affecting the efficacy of deep EMR; Methods Retrospective analysis was made on 45 patients with chronic myeloid leukemia in the chronic phase admitted to the hematology department of our hospital from December 2016 to December 2020, who were all given nilotinib first-line treatment. Peripheral blood samples were collected at 3 and 6 months after treatment to detect BCR/ABLIS levels to evaluate the deep EMR molecular reaction, record the occurrence of adverse reactions, and follow up to December 2021 to record the progression free survival period; The clinical data of patients were collected and the influencing factors of deep EMR were analyzed; Results The EMR response rate (early molecular biological response: BCR/ABLIS molecular level lower than 10% in 3 months, BCR/ABLIS molecular level lower than 1% in 6 months, and BCR/ABLIS molecular level lower than 0.1% in 12 months) was 82.3%, 92.1%, 86.2% respectively after the first line treatment of nilotinib for 3, 6, and 12 months, and the non-obtained EMR was 17.7% and 7.9% respectively after the first line treatment of nilotinib for 3 and 6 months; The depth of EMR (BCR/ABLIS molecular level was lower than 1% at 3 months and lower than 0.1% at 6 months) was 68.6% and 50.9%, respectively after the first line treatment of nilotinib for 3 and 6 months. At 12 months of treatment, the rate of major molecular response (MMR, BCR/ABLIS level ≤ 0.1%) was 44 cases (86.2%); The median time to reach MMR was 4 (3-17) months; Adverse reactions: neutropenia (4.4%), thrombocytopenia (6.7%), anemia (2.2%), all of which are grade 1 to 2, can be recovered in a short time without grade 3 to 4 hematological adverse reactions; The non hematological adverse reactions were skin rash (4.4%), pruritus (4.4%), nausea (2.2%), which were tolerable and could be relieved after symptomatic treatment without changing the drug dosage; Survival: The progression free survival rate was 98% (50/51); The results of univariate analysis showed that the course of disease before nilotinib, platelet count, hemoglobin, peripheral blood primitive cells and the length of subcostal spleen were all related to the depth of EMR obtained by CML patients, and the difference was statistically significant (P<0.05, see Table 1); The above clinical parameters were introduced into the multifactor Logistic regression analysis model, and the results showed that only the presence of primitive cells in peripheral blood and megasplenomegaly (≥ 7cm under splenic rib) were independent risk factors for patients to obtain deep EMR, P<0.05. Conclusion The efficacy of deep EMR is an important indicator in the era of treatment free remission (TFR) for CML patients. Nilotinib can obtain a high proportion of deep EMR in the first-line treatment of chronic myeloid leukemia, with high safety; The presence of primitive cells in peripheral blood and splenomegaly were independent risk factors for patients to obtain deep EMR.

Objective To explore the application effect of mind mapping in donors education before peripheral blood hematopoietic stem cells (PBSC) donation. Methods A total of 67 donors who underwent PBSC donation for the first time between March 2021 and December 2021 were divided into the control group (32 cases,20 cases of allogeneic donors and 12 cases of autologous donors) and the observation group (35 cases,22 cases of allogeneic donors and 13 case of autologous donors). Donors in the control group received traditional oral education,while donors in the observation group received oral education combined with mind mapping. After pre-donation education,Self-rating Anxiety Scale (SAS) were applied to evaluate the anxiety of donors,while Self-rating Depression Scale (SDS) were applied to evaluate the depression of donors. Donor satisfaction was investigated after donation. Results The negative emotions levels of anxiety (SAS) and depression (SDS) in the observation group were significantly lower than those in the control group,and the degree of satisfaction in the observation group was significantly higher than that in the control group. Conclusion The application of mind mapping in education before donation can help to reduce the anxiety and depression levels of donors,and improve the work efficiency of nursing staff and the satisfaction of both nurses and donors.

With the increasing aging of Chinese population in the coming decades, plasma collection will have a huge impact. How to improve the comprehensive utilization of plasma is an urgent problem to be solved in the industry. In this paper, the collection of raw plasma, the types and preparation process of plasma protein products, the research status of plasma protein, and the regulations to promote the comprehensive utilization of plasma were reviewed. At present, the types of plasma protein products in China are increasing, and relevant policies to promote the comprehensive utilization of plasma are constantly introduced. However, compared with foreign countries, China manufacturers are small in scale, lack of motivation for research and development of new products and new technologies, and lack of in-depth research on plasma protein products. The merger and acquisition of plasma protein products enterprises, the strengthening of industry-university-research cooperation, and the improvement of scientific research strength will be the direction of future development.